Seven questions. A clear picture of where your biomarker strategy stands relative to your development phase, and what to do next.
Below is an example of the outcome presented in a radar chart. Each question represents a critical function that should be part of your biomarker strategy. Your answers are compared to the expected level of progression for a given phase of drug development. The graph indicates strengths, where you are ahead of schedule, or weaknesses that need more attention.
The questionnaire presented here is a quick scan, aimed to provide an overview within a minute. If you want more depth, I can review your plans in full and help you close the gaps. See below for the extended virtual 360 biomarker advisory board.

Biomarker 360 Virtual Advisory Board
Have your biomarker strategy reviewed and scrutinized by 9 virtual experts in critical domains. An AI-structured review across 9 expert lenses, interpreted and validated by Stefan Kostense.

The expert panel
•Clinical Development
•Practicing Physician
•Biomarker Discovery
•Translational Science
•Regulatory
•Market Access
•Bioanalysis
•Statistics
•Patient Advocacy


The Debate
The virual experts enter in discussion about your biomarker startegy and plans. This results in individual scores for each of the domains.


Nulla euismod
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla euismod condimentum felis vitae efficitur.


Nulla euismod
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla euismod condimentum felis vitae efficitur.
